Propranolol treatment for chylothorax after congenital cardiac surgery

Objective: Postoperative chylothorax causes significant morbidities in pediatric patients with cardiac disease. New treatment approaches based on evolving understanding of underlying lymphatic dysfunction are being developed. We hypothesized that propranolol reduces morbidities and duration of chest tube requirement in high-output chylous effusion. Methods: The postoperative courses of 50 pediatric patients with cardiac disease and high-output chylous effusion (control, n = 25; propranolol-treated, n = 25) were reviewed, including morbidities, length of hospitalization, and duration of chest tube requirement. Statistical analysis was performed using Welch's t test, Kruskal-Wallis tests for continuous variables, and chi-square and Fisher exact tests for categorical variables. Univariable logistic regression was used to determine predictors of response. Results: Propranolol response was defined as 80% or more drainage reduction in 9 days or less. Treated patients were grouped into responders (<9 days) and nonresponders (>10 days). Neither initial amount of drainage (P =.12) nor day of propranolol initiation (P =.17) correlated with response. When compared with controls and nonresponders, responders had significantly fewer days with chest tube requirement (P<.01), infection (P<.0002), and thrombus (P =.005), and shorter hospitalization (P<.05). All patients had low serum albumin, although nonresponders had significantly decreased serum albumin when compared with responders and control patients (P <.002), and were more likely to receive albumin replacement (P<.01). Malnutrition was prevalent in all patient groups. Conclusions: Responders to propranolol had significantly less morbidity and duration of chest tube requirement when compared with control patients and nonresponders. Nonresponders did not have worse outcomes than control patients. We conclude that propranolol may be an effective treatment of patients with refractory chylothorax.